Author of

• 30943

  +

  P2.04 - Immuno-oncology (ID 167)

  • Event: WCLC 2019
  • Type: Poster Viewing in the Exhibit Hall
  • Track: Immuno-oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall

  • 30983

    +

    P2.04-35 - Immune Related Adverse Events in NSCLC Patients Treated with Immune Checkpoint Therapy Who Received the Influenza Vaccination vs No Vaccination (ID 836)

    10:15 - 18:15  |  Author(s): Shannon Hough
    • Abstract

    Background
    

    The influenza vaccination is recommended by the CDC for cancer patients to reduce the risk of influenza-related complications. There is concern that the incidence of immune-related adverse events (irAEs) may be greater in vaccinated patients receiving immune checkpoint inhibitors (ICPI). We sought to interrogate if influenza vaccination in patients with NSCLC receiving ICPI therapy had an increased incidence of iRAEs compared to non-vaccinated patients using data from our single-center experience.

    Method
    

    We conducted a single-center retrospective analysis of patients with advanced NSCLC who received PD-1 or PD-L1 inhibitor monotherapy between March 2015 – December 2018. Influenza immunization records from both institutional and state-wide immunization registries were obtained for each patient identified between 2014 -2019. Comparisons of adverse event incidence between flu vaccinated vs control patients were tested using chi-square statistics.

    Result
    

    117 patients were included in our analysis, 33 patients (28%) were vaccinated during ICPI therapy, 19 (58%) received quadrivalent influenza vaccine, 13 (39%) patients received trivalent influenza vaccine and 1 (3%) was unable to be determined. 22 (67%) of vaccinated patients had an irAE vs 53 (63%) of patients who were not vaccinated during ICPI therapy (p = 0.720). Eight (24%) vaccinated patients had irAE leading to discontinuation of therapy vs 12 (14%) patients who were not vaccinated during ICPI therapy (p = 0.198). The most frequent irAE in both groups was fatigue 16 (48%) vs 28 (33%) (p=0.128). Notable irAEs included colitis (0), pneumonitis (3), hepatitis (1) with vaccination vs. colitis (1), pneumonitis (3), hepatitis (4) without vaccination. There were no statistically significant differences in baseline demographics between both groups including age, race, gender, tumor histology or ECOG performance status.

    Conclusion
    

    Our retrospective study suggests that in general, irAEs are not significantly increased with vaccination for influenza during treatment with immune checkpoint inhibitors. However, there is a slight trend toward increased incidence of irAE warranting ICPI discontinuation and further investigation is warranted. Limitations of this study include a small sample size and inability to grade irAE retrospectively.